Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:50 AM EDT

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2785–2808 of 10,533 matching trials from the local directory fallback.

Filters: Active, not recruiting Clear all

Conditions: Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
Interventions: Albumin-Bound Paclitaxel, Gemcitabine, Nivolumab Injection [Opdivo], TST001, mFOLFOX6; Drug
Lead sponsor: Transcenta Therapeutics (Hangzhou) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 18
States / cities: Gilbert, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more

Conditions: Solid Tumors, KRAS Mutation; SOS1
Interventions: BI 1701963, Trametinib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • Charlotte, North Carolina • Nashville, Tennessee + 1 more

Conditions: Meningioma
Interventions: Lutathera; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: New York, New York • Cleveland, Ohio

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Durvalumab, Echocardiography Test, Magnetic Resonance Imaging, Olaparib, X-Ray Imaging; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 17
States / cities: Buena Park, California • Los Angeles, California • Newport Beach, California + 10 more

Conditions: Hematological Malignancies, Pediatric Cancer, Solid Tumor Pediatric
Interventions: Durvalumab / Tremelimumab Combination Therapy; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 0 Years to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 5
States / cities: Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 2 more

Conditions: Acute Myelogenous Leukemia
Interventions: DC/AML fusion cells; Biological
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Brain Metastases, Small Cell Lung Cancer
Interventions: Stereotactic Radiation; Radiation
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Brain Metastases
Interventions: Stereotactic radiation (SRS), Whole brain radiation; Radiation
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Acute Myelogenous Leukemia
Interventions: DC/AML Fusion Vaccine, Observation; Biological · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • Madison, Wisconsin

Conditions: Healthy Subjects
Interventions: Aldosterone response to AngII LS, Renal blood flow response to salt, Vascular Stiffness; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 25 Years to 45 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Malignant Bone Neoplasm
Interventions: Activity Monitor, Exercise Intervention; Device · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 5 Years to 39 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Solid Tumors
Interventions: Cyclophosphamide, Fludarabine, IP Catheter Insertion, Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells, Production of Genetically-modified T cells; Drug · Device · Genetic + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Neoplasms
Interventions: Radiation with Concurrent Chemotherapy; Radiation
Lead sponsor: Proton Collaborative Group; Network
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 6
States / cities: Jacksonville, Florida • Warrenville, Illinois • Baltimore, Maryland + 3 more

Conditions: Breast Cancer, Breast Neoplasm, Breast Tumor, Cancer of the Breast
Interventions: Proton Radiotherapy; Radiation
Lead sponsor: Proton Collaborative Group; Network
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2032
U.S. locations: 5
States / cities: Warrenville, Illinois • Baltimore, Maryland • Somerset, New Jersey + 2 more

Conditions: Prostate Cancer
Interventions: Proton Radiation Hypofractionation, Proton Radiation Standard Fractionation; Radiation
Lead sponsor: Proton Collaborative Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 5
States / cities: Phoenix, Arizona • Warrenville, Illinois • Baltimore, Maryland + 2 more

Conditions: Chondrosarcoma
Interventions: Proton Beam Therapy; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: Voice of Sleep "MamaBee" training modules (Fairy Tales); Device
Lead sponsor: Pisareva Citadel Group LLC; Other
Eligibility: 8 Years to 18 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: NewYork, New York

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 2,607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Pulmonary Arterial Hypertension
Interventions: MTT with antibiotic preconditioning + fiber supplementation, MTT with antibiotic preconditioning + placebo supplementation, MTT with placebo + placebo supplementation.; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Overweight or Obesity and Elevated Liver Fat
Interventions: Maridebart cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 23
States / cities: Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 17 more

Conditions: Anxiety, Generalized Anxiety Disorder (GAD), Worrying
Interventions: Progressive Muscle Relaxation (PMR), Safety Behavior Fading for Pathological Worry; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: SARS-CoV-2
Interventions: Placebo, mRNA-1273, mRNA-1283; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 30,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 150
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more

Conditions: Allogenic Hematopoietic Cell Transplant, Physical Activity, Sleep
Interventions: Fitbit, Questionnaire; Device · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Arsenic Poisoning, Environmental Exposure, Water-Related Diseases
Interventions: Water Pitcher Filtration System; Behavioral
Lead sponsor: Trustees of Dartmouth College; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Search by objective public record fields.

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

Durvalumab and Tremelimumab for Pediatric Malignancies

Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients

Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission

Lysine-specific Demethylase 1 and Salt-sensitivity in Humans

Supervised Exercise in Improving Physical Fitness Before Surgery in Patients With Resectable Bone Cancer

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer

Proton Radiation for Stage II/III Breast Cancer

Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer

Proton Beam Therapy for Chondrosarcoma

Methodology of Super-Early Training of Developer Engineers and Leading Analysts With a Diagnosis of ADHD/ASD for Ensuring the Engineering Sovereignty of the State: Time Horizon: 2026-2038-2050

A Study of Disease Modifying Therapy Use in Women With Multiple Sclerosis Before, During, and After Pregnancy

Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in PAH.

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Text Message Safety Behavior Fading for Pathological Worry

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

Sleep and Physical Activity in Patient and Caregiver Dyads Following Allogeneic Hematopoietic Cell Transplantation

Table-Top Water Pitcher to Reduce Arsenic Exposure Among Well Users in New Hampshire